Valuation: Cosmos Holdings Inc.

Market Cap 30.99M 27.75M 25.53M 23.13M 43.23M 2.94B 44.04M 304M 122M 1.55B 116M 114M 4.88B P/E 2026 *
-2.05x
P/E 2027 * 4.4x
Enterprise Value 30.99M 27.75M 25.53M 23.13M 43.23M 2.94B 44.04M 304M 122M 1.55B 116M 114M 4.88B EV / Sales 2026 *
0.36x
EV / Sales 2027 * 0.24x
Free-Float
74.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 65 28/04/2022
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 30.99M
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +0.99%+5.90%+46.59%+83.14% 473.55B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 85.41M 76.49M 70.36M 63.75M 119M 8.11B 121M 839M 337M 4.27B 321M 314M 13.45B 130M 116M 107M 96.74M 181M 12.31B 184M 1.27B 511M 6.47B 486M 476M 20.41B
Net income 5.97M 5.34M 4.91M 4.45M 8.32M 566M 8.48M 58.61M 23.53M 298M 22.39M 21.91M 940M 8.81M 7.89M 7.26M 6.58M 12.3M 837M 12.53M 86.57M 34.75M 440M 33.07M 32.37M 1.39B
Net Debt - -
Projected Income Statement - Annual - Cosmos Holdings Inc.
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cosmos Holdings Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3079USD
Average target price
2.950USD
Spread / Average Target
+858.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cosmos Holdings Inc.